Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 44% less
These brands contain the same active ingredient (Oxcarbazepine). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Oxcarb XR is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Adults: treatment is started at 600 mg a day, given in two divided doses. Adjunctive therapy: the dose may be raised by no more than 600 mg a day at roughly weekly intervals, to a recommended daily dose of 1200 mg a day. Conversion to monotherapy: the concomitant antiepileptic drug is withdrawn over 3 to 6 weeks, while the maximum dose of oxcarbazepine is reached within 2 to 4 weeks by increments of 600 mg a day at weekly intervals, up to a recommended daily dose of 2400 mg a day. Initiation of monotherapy: the dose is increased by 300 mg a day every third day, up to 1200 mg a day. For patients with a creatinine clearance below 30 mL/min, treatment is started at half the usual starting dose and increased slowly. Pediatrics: treatment is started at 8 to 10 mg/kg a day, given in two divided doses. For patients aged 2 to under 4 years and weighing under 20 kg, a starting dose of 16 to 20 mg/kg a day may be considered. The recommended daily dose depends on the patient's weight. Adjunctive patients aged 2 to 16 years: for patients aged 4 to 16 years, the target maintenance dose should be reached over 2 weeks; for patients aged 2 to under 4 years, the maximum maintenance dose should be reached over 2 to 4 weeks and should not exceed 60 mg/kg a day. Conversion to monotherapy for patients aged 4 to 16 years: the dose may be raised by no more than 10 mg/kg a day at weekly intervals, and the concomitant antiepileptic drugs can be fully withdrawn over 3 to 6 weeks. Initiation of monotherapy for patients aged 4 to 16 years: the dose is increased by 5 mg/kg a day every third day.
Side Effects
Clinical trials show that Leptal is better tolerated than carbamazepine. The most common adverse effects were: Central nervous system: dizziness, diplopia, headache, nystagmus and abnormal gait; GI: nausea, vomiting and abdominal pain; Dermatologic: rash; Serum electrolytes: hyponatremia. Bone marrow suppression and hepatotoxicity, which are associated with carbamazepine, were infrequently reported with Leptal.
Cautions & Contraindications
Warnings & Precautions
Cognitive and neuropsychiatric effects, such as psychomotor slowing, difficulty concentrating, language problems, drowsiness or fatigue, ataxia and gait disturbances, are among the common adverse effects associated with Leptal. Cases of asymptomatic hyponatraemia (low blood sodium) have been reported. Monitoring of serum sodium levels should be considered if the patient is taking other medicines known to lower serum sodium, or if symptoms of hyponatraemia develop, such as nausea, malaise, headache or confusion. Patients with a history of hypersensitivity reaction to carbamazepine should be treated with Leptal only.
Contraindications
Oxcarbazepine must not be given to anyone with a known allergy to Oxcarbazepine, to any of the ingredients in the preparation, or to eslicarbazepine acetate.